Alkem Laboratories has launched NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy. NeuCeno is a once daily oral therapy, and is available in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg tablets.
Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition. Despite the availability of multiple anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, substantially affecting their independence, daily functioning and overall quality of life.
Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.
